Abstract: There is described a process for the preparation of Cannabidiol (CBD) and derivatives thereof of formula I: (I) in which R1 is H or —COOR2; 10 wherein R2 is C1-6alkyl or aryl; said process comprising contacting a solution of (+)-p-mentha-diene-3-ol, or an ester thereof, with a compound of formula II: (II) in which R1 and R2 are each as herein defined; and an ion-exchange resin as a catalyst.

Abstract: The present invention relates to a highly economic process for the purification of a cannabinoid acid, more specifically THCA or CBDA, from either a crude cannabis plant material or a cell culture of said cannabis plant, using ion exchange resins. The purified cannabinoid acid obtained may then be decarboxylated to yield the corresponding cannabinoid, i.e., THC or CBD, respectively.

Abstract: The present invention relates to a highly economic process for the purification of a cannabinoid acid, more specifically THCA or CBDA, from either a crude cannabis plant material or a cell culture of said cannabis plant, using ion exchange resins. The purified cannabinoid acid obtained may then be decarboxylated to yield the corresponding cannabinoid, i.e., THC or CBD, respectively.

Abstract: THCA- and CBDA-derivatives can be formulated in pharmaceutical compositions. The derivatives are non-classical cannabinoids that are either agonists or antagonists of the peripheral CB1 and/or CB2 receptors, and are thus useful for CB1 and/or CB2 receptor activation/deactivation, such as for preventing, alleviating, or treating medical conditions that benefit from CB1 and/or CB2 receptor agonist/antagonist treatment.

Abstract: The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents.

Abstract: The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents.

Abstract: The present invention relates to novel benzofuran compounds, to pharmaceutical compositions that include such compounds, and to methods of use thereof. Certain compounds of the invention share some pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, compounds of the invention are useful as analgesic, neuroprotective, immunomodulatory and anti-inflammatory agents.

Abstract: A photochromic compound for incorporation into plastic articles, particularly into a plastic lens, is selected from a spiro(indoline)naphtho(2,1-b)(1,4)oxazine and a spiro(indoline)naphtho(1,2-b)(1,4)oxazine containing a group selected from: (a) —CH2—CnF2n+1 at the nitrogen atom in the 1-position on the indoline part of the molecule, wherein n is an integer of 1 to 6; (b) —COOR at the 3-position on the indoline part of the molecule, wherein R is (i) C1-C6 alkyl optionally substituted by fluoro, C1-C4 alkoxy or fluoroalkoxy, C1-C4 alkylcarbonyloxy, C2-C4 alkenylcarbonyloxy, C3-C6 cycloalkyl or aryl; (ii) C2-C6 alkenyl with a terminal double bond; (iii) C3-C6 cycloalkyl optionally substituted by fluoro; or (iv) aryl; (c) an —OCF3 group on the benzene ring of the indoline part of the molecule; (d) an aryl(dialkyl)methyl group of the formula —C(aryl)(CnH2n+1)(CmH2m+1), wherein n and m are integers from 1 to 5, linked to one of the benzene rings of the naphthoxazine part of the molecule; and (e) any combination of

Abstract: A photochromic compound for incorporation into plastic articles, particularly into a plastic lens, is selected from a spiro(indoline)naphtho(2,1-b) (1,4)oxazine and a spiro(indoline)naphtho(1,2-b) (1,4)oxazine containing a group selected from: (a) —CH2—CnF2n+1 at the nitrogen atom in the 1-position on the indoline part of the molecule, wherein n is an integer of 1 to 6; (b) —COOR at the 3-position on the indoline part of the molecule, wherein R is (i) C1-C6 alkyl optionally substituted by fluoro, C1-C4 alkoxy or fluoroalkoxy, C1-C4 alkylcarbonyloxy, C2-C4 alkenylcarbonyloxy, C3-C6 cycloalkyl or aryl; (ii) C2-C6 alkenyl with a terminal double bond; (iii) C3-C6 cycloalkyl optionally substituted by fluoro; or (iv) aryl; (c) an —OCF3 group on the benzene ring of the indoline part of the molecule; (d) an aryl(dialkyl)methyl group of the formula —C(aryl) (CnH2n+1) (CmH2m+1), wherein n and m are integers from 1 to 5, linked to one of the benzene rings of the naphthoxazine